PPARGC1A and cardiac hypertrophy: He et al. (13) have identified that canagliflozin could improve myocardial hypertrophy, fibrosis, and cardiac function induced by hypertension in dahl salt-sensitive rats via activating the AMPK/SIRT1/PGC1α pathway, which was highly associated with energy metabolism and oxidative stress.